60 Degrees Pharmaceuticals Advances Tafenoquine for Chronic Babesiosis as Phase 2 Study Clears Safety Hurdle — 60 Degrees Pharmaceuticals, Inc.

Event summary

60 Degrees Pharmaceuticals' Phase 2 B-FREE study for chronic babesiosis received a positive safety recommendation from the Data Safety Monitoring Board after reviewing initial patient data.
The study evaluates tafenoquine (ARAKODA®) in treating severe fatigue in chronic babesiosis patients, with no FDA-approved treatments currently available.
Babesiosis incidence is rising rapidly, particularly in the Northeast, with at least 25,000 cases annually according to insurance claims research.
Tafenoquine is already approved for malaria prophylaxis but not for babesiosis treatment.

The big picture

60 Degrees Pharmaceuticals is leveraging its existing malaria drug, tafenoquine, to address a critical unmet need in chronic babesiosis treatment. The rising incidence of this tick-borne disease, coupled with the lack of FDA-approved therapies, presents a significant market opportunity. Success in this indication could expand tafenoquine's commercial potential beyond malaria prophylaxis into a broader vector-borne disease portfolio.

What we're watching

Clinical Efficacy: Whether tafenoquine demonstrates significant efficacy in resolving chronic fatigue in babesiosis patients by the study's primary endpoint at Day 90.
Regulatory Pathway: The pace at which 60 Degrees Pharmaceuticals can secure FDA approval for tafenoquine as a treatment for babesiosis, given its existing malaria prophylaxis indication.
Market Opportunity: How the company positions tafenoquine in an expanding market for treatments targeting persistent symptoms of tick-borne diseases and long-term syndromes like long COVID.